![]() ![]() PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin. ![]() It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. Infrastructure to maximize access to trabectedin to all patients with sarcoma or ovarian cancer". Former product licensee Janssen will continue to commercialize the product in this territory, until its marketing authorizations are formally transferred to ADIUM.Īccording to Luis Mora, Managing Director of PharmaMar's Oncology Business Unit, " We are pleased to have partnered Yondelis ® with ADIUM for the Latin American market with more than 20 countries. Through this new alliance, ADIUM will also pursue additional regulatory approvals, as well as public price approval where not yet conceded. Trabectedin is currently provided by Janssen to patients in most of Latin American countries, for the treatment of soft tissue sarcoma and relapsed ovarian cancer. This new agreement follows PharmaMar's announcement on August 26 th, 2019, regarding the agreement entered into with Janssen Products LP (Janssen), by which PharmaMar recovered the commercialization rights of the product in more than 40 countries, formerly licensed to Janssen, where trabectedin has already been approved. PharmaMar will retain exclusive production rights of the product and will sell the product to ADIUM for its clinical and commercial use. Under the terms of the agreement, PharmaMar will receive a non-disclosed upfront payment and will be eligible for additional remunerations, including regulatory milestone payments. to commercialize the marine-derived anticancer drug Yondelis ® (trabectedin) in Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Curacao, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Trinidad and Tobago, Uruguay and Venezuela. PharmaMar (MSE:PHM) has announced today a licensing agreement with ADIUM Pharma S.A. PharmaMar will receive an upfront payment and is eligible for additional remunerations, including regulatory milestone payments.to commercialize Yondelis ® in Latin America Pfizer has the only other fully authorized vaccine in the U.S., cleared last August.PharmaMar signs a new agreement with ADIUM PHARMA S.A. Food and Drug Administration for people 18 and older, an important milestone that will let Moderna market the vaccine to adults under the brand name Spikevax. ![]() Moderna’s shot won full approval in January from the U.S. The partnership with Adium will extend beyond Covid vaccines and into Moderna’s oncology and rare autoimmune diseases treatments, among others. The companies will focus on obtaining full approval for its vaccine in the region and believe by 2023 that Moderna will start marketing its shot beyond bilateral agreements with governments, “depending on how the pandemic evolves,” Saglio said. And the company has recently announced agreements with Colombia and Chile to supply them with millions of doses. A total of 15 countries are expected to have access to Moderna’s shots this year either through direct agreements with governments or through the international Covax initiative, Saglio said. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |